GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calidi Biotherapeutics Inc (AMEX:CLDI) » Definitions » Capex-to-Operating-Income

CLDI (Calidi Biotherapeutics) Capex-to-Operating-Income : 0.00 (As of Mar. 2025)


View and export this data going back to 2023. Start your Free Trial

What is Calidi Biotherapeutics Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Calidi Biotherapeutics's Capital Expenditure for the three months ended in Mar. 2025 was $-0.01 Mil. Its Operating Income for the three months ended in Mar. 2025 was $-5.01 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.

Calidi Biotherapeutics Capex-to-Operating-Income Historical Data

The historical data trend for Calidi Biotherapeutics's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calidi Biotherapeutics Capex-to-Operating-Income Chart

Calidi Biotherapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Operating-Income
- - - - -

Calidi Biotherapeutics Quarterly Data
Dec20 Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Calidi Biotherapeutics's Capex-to-Operating-Income

For the Biotechnology subindustry, Calidi Biotherapeutics's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Calidi Biotherapeutics's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Calidi Biotherapeutics's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Calidi Biotherapeutics's Capex-to-Operating-Income falls into.


;
;

Calidi Biotherapeutics Capex-to-Operating-Income Calculation

Calidi Biotherapeutics's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.016) / -21.595
=N/A

Calidi Biotherapeutics's Capex-to-Operating-Income for the quarter that ended in Mar. 2025 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.007) / -5.012
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Calidi Biotherapeutics  (AMEX:CLDI) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

Calidi Biotherapeutics Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Calidi Biotherapeutics's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Calidi Biotherapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calidi Biotherapeutics Inc (AMEX:CLDI) » Definitions » Capex-to-Operating-Income
Comparable Companies
INAB AFMD ABVC PHGE BIVI EQ MBRX BOLT ZEOX SABS VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
4475 Executive Drive, Suite 200, San Diego, CA, USA, 92121
Website
https://www.calidibio.com
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.